Join
Live feed
·
INSIDERFilingvia Quantisnow
Esperion Therapeutics Inc. logo

President and CEO Koenig Sheldon L. was granted 840,000 shares, increasing direct ownership by 113% to 1,585,009 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ESPR· Esperion Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ESPR (Esperion Therapeutics Inc.) and more on Quantisnow.